• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与成熟囊性畸胎瘤相关的卵巢黏液性肿瘤:形态学和免疫组化分析确定了一个潜在畸胎瘤起源的亚组,该亚组具有在卵巢中更常见的作为继发性肿瘤的下消化道黏液性肿瘤的特征。

Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.

作者信息

Vang Russell, Gown Allen M, Zhao Chengquan, Barry Todd S, Isacson Christina, Richardson Mary S, Ronnett Brigitte M

机构信息

Department of Pathology and Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Am J Surg Pathol. 2007 Jun;31(6):854-69. doi: 10.1097/PAS.0b013e31802efb45.

DOI:10.1097/PAS.0b013e31802efb45
PMID:17527072
Abstract

Most primary ovarian mucinous tumors are of surface epithelial-stromal origin and exhibit diffuse expression of cytokeratin 7 (CK7) combined with variable expression of cytokeratin 20 (CK20); this immunoprofile distinguishes them from most lower gastrointestinal tract tumors secondarily involving the ovaries. The uncommon ovarian mucinous tumors of germ cell (teratomatous) origin have not been extensively evaluated to determine the utility of these markers and other markers of intestinal differentiation for distinguishing these tumors from metastatic gastrointestinal tract mucinous tumors. Immunohistochemical expression of CK7, CK20, CDX2, and villin was assessed in 44 ovarian mucinous tumors associated with a mature cystic teratoma. All cases lacked evidence of a nonovarian primary mucinous tumor. All mucinous tumors were unilateral; 6 cases had bilateral teratomas. All tumors displayed gastrointestinal-type mucinous differentiation, with epithelium that was commonly goblet cell-rich or hypermucinous; 21 were associated with pseudomyxoma ovarii and 3 of these had pseudomyxoma peritonei. Tumor architecture ranged from purely cystadenomatous (n=24), to proliferative (n=13), to carcinomatous (n=6); some tumors had admixtures of these patterns. One tumor had a goblet cell carcinoidlike pattern with pseudomyxoma ovarii. Three carcinomas had a signet ring cell component. Cystadenomatous tumors without pseudomyxoma ovarii (n=15) exhibited all possible CK7/CK20 coordinate expression profiles with nearly equal frequency. All proliferative tumors without pseudomyxoma ovarii (n=8) expressed CK7, most often in combination with CK20 expression. All cystadenomatous and proliferative tumors with pseudomyxoma ovarii (n=9 and n=5) were CK7-/CK20+. All carcinomatous tumors had pseudomyxoma ovarii; 3 were CK7-/CK20+, 2 were CK7+/CK20+, and 1 was CK7+/CK20-. The presence of pseudomyxoma ovarii was significantly associated with a CK7-/CK20+ profile (86% with pseudomyxoma ovarii vs. 13% without, P<0.0001), CDX2 positivity (79% vs. 0%, P<0.0001), and villin positivity (57% vs. 5%, P=0.0009). A subset of mucinous tumors associated with mature cystic teratomas exhibiting morphologic and immunohistochemical features of lower intestinal tract-type mucinous tumors may be teratomatous in origin. In practice, the more common diagnosis of secondary involvement by a lower intestinal tract mucinous tumor should be addressed in the pathology report and in subsequent clinical evaluation; interpretation as a true primary ovarian mucinous tumor of teratomatous origin can be considered as an alternative diagnosis when evaluation and follow-up fail to identify a nonovarian source of the mucinous tumor. Those tumors having CK7 expression with or without CK20 expression may be derived from upper gastrointestinal tract-type or sinonasal-type teratomatous elements but could be independent tumors of surface epithelial-stromal origin.

摘要

大多数原发性卵巢黏液性肿瘤起源于表面上皮-间质,表现为细胞角蛋白7(CK7)弥漫性表达,并伴有细胞角蛋白20(CK20)的不同程度表达;这种免疫表型将它们与大多数继发累及卵巢的下消化道肿瘤区分开来。起源于生殖细胞(畸胎瘤性)的罕见卵巢黏液性肿瘤尚未得到广泛评估,以确定这些标志物以及其他肠分化标志物在区分这些肿瘤与转移性胃肠道黏液性肿瘤方面的效用。对44例与成熟囊性畸胎瘤相关的卵巢黏液性肿瘤进行了CK7、CK20、CDX2和绒毛蛋白的免疫组化表达评估。所有病例均无非卵巢原发性黏液性肿瘤的证据。所有黏液性肿瘤均为单侧;6例有双侧畸胎瘤。所有肿瘤均显示胃肠道型黏液分化,上皮通常富含杯状细胞或黏液过多;21例与卵巢黏液瘤相关,其中3例有腹膜黏液瘤。肿瘤结构从单纯囊腺瘤性(n = 24)到增生性(n = 13)再到癌性(n = 6)不等;一些肿瘤具有这些模式的混合。1例肿瘤具有杯状细胞类癌样模式并伴有卵巢黏液瘤。3例癌有印戒细胞成分。无卵巢黏液瘤的囊腺瘤性肿瘤(n = 15)表现出所有可能的CK7/CK20协同表达模式,频率几乎相等。所有无卵巢黏液瘤的增生性肿瘤(n = 8)均表达CK7,最常见的是与CK20共同表达。所有伴有卵巢黏液瘤的囊腺瘤性和增生性肿瘤(n = 9和n = 5)均为CK7 - /CK20 +。所有癌性肿瘤均有卵巢黏液瘤;3例为CK7 - /CK20 +,2例为CK7 + /CK20 +,1例为CK7 + /CK20 -。卵巢黏液瘤的存在与CK7 - /CK20 +模式(有卵巢黏液瘤者为86%,无者为13%,P<0.0001)、CDX2阳性(79% vs. 0%,P<0.0001)和绒毛蛋白阳性(57% vs. 5%,P = 0.0009)显著相关。与成熟囊性畸胎瘤相关的一部分黏液性肿瘤表现出下肠道型黏液性肿瘤的形态学和免疫组化特征,其起源可能是畸胎瘤性。在实际操作中,病理报告和后续临床评估中应考虑更常见的下肠道黏液性肿瘤继发累及的诊断;当评估和随访未能发现黏液性肿瘤的非卵巢来源时,将其解释为真正的原发性卵巢畸胎瘤性黏液性肿瘤可作为一种替代诊断。那些有或无CK20表达的CK7表达的肿瘤可能源自上消化道型或鼻旁窦型畸胎瘤成分,但也可能是表面上皮-间质起源的独立肿瘤。

相似文献

1
Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary.与成熟囊性畸胎瘤相关的卵巢黏液性肿瘤:形态学和免疫组化分析确定了一个潜在畸胎瘤起源的亚组,该亚组具有在卵巢中更常见的作为继发性肿瘤的下消化道黏液性肿瘤的特征。
Am J Surg Pathol. 2007 Jun;31(6):854-69. doi: 10.1097/PAS.0b013e31802efb45.
2
Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.伴有黏液性上皮性肿瘤的卵巢成熟畸胎瘤:形态学异质性及与腹膜假黏液瘤的关联
Am J Surg Pathol. 2008 May;32(5):645-55. doi: 10.1097/PAS.0b013e31815b486d.
3
Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases.细胞角蛋白7和20在卵巢原发性和继发性黏液性肿瘤中的表达:179例病例的免疫组化联合表达谱及染色分布分析
Am J Surg Pathol. 2006 Sep;30(9):1130-9. doi: 10.1097/01.pas.0000213281.43036.bb.
4
Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7.CDX2在原发性卵巢黏液性肿瘤及累及卵巢的转移性黏液癌中的免疫组化表达:与CK20的比较及与CK7协同表达的相关性
Mod Pathol. 2006 Nov;19(11):1421-8. doi: 10.1038/modpathol.3800698. Epub 2006 Sep 15.
5
CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.使用 CK7、CK20、CDX2 和 MUC2 免疫组织化学染色来区分转移性结直肠癌累及卵巢与原发性卵巢黏液性腺癌。
Jpn J Clin Oncol. 2010 Mar;40(3):208-13. doi: 10.1093/jjco/hyp150. Epub 2009 Nov 18.
6
The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic.SATB2在卵巢肠型黏液性肿瘤鉴别诊断中的价值:原发性与转移性。
Ann Diagn Pathol. 2015 Aug;19(4):249-52. doi: 10.1016/j.anndiagpath.2015.05.004. Epub 2015 May 21.
7
Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour.成熟囊性畸胎瘤中发生的卵巢黏液性肿瘤并伴有腹膜假黏液瘤:两例报告并与低级别阑尾黏液性肿瘤累及卵巢相比较
Pathology. 2006 Dec;38(6):534-8. doi: 10.1080/00313020601024078.
8
Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.原发性卵巢类癌肿瘤可能表达尾型同源盒转录因子2(CDX-2):这是在鉴别卵巢转移性肠类癌肿瘤时的一个潜在陷阱。
Int J Gynecol Pathol. 2009 Jan;28(1):41-8. doi: 10.1097/PGP.0b013e31817a8f51.
9
The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.Cdx2免疫染色在鉴别原发性卵巢癌与转移至卵巢的结肠癌中的价值。
Int J Gynecol Pathol. 2004 Jan;23(1):52-7. doi: 10.1097/01.pgp.0000101141.31270.a0.
10
SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.SATB2表达可区分结直肠和阑尾来源的卵巢转移瘤与黏液性或子宫内膜样型原发性卵巢肿瘤。
Am J Surg Pathol. 2016 Mar;40(3):419-32. doi: 10.1097/PAS.0000000000000553.

引用本文的文献

1
Mucinous adenocarcinoma arising from a mature cystic teratoma of the ovary in a pediatric patient: A rare case report.一名儿科患者卵巢成熟性囊性畸胎瘤发生黏液性腺癌:一例罕见病例报告。
Radiol Case Rep. 2025 Aug 22;20(11):5663-5667. doi: 10.1016/j.radcr.2025.07.055. eCollection 2025 Nov.
2
Mucinous Carcinoma, Mucinous Borderline Tumor and Pseudomyxoma Ovarii in a Cystic Teratoma: A Histological Conundrum.囊性畸胎瘤中的黏液性癌、黏液性交界性肿瘤及卵巢假黏液瘤:一个组织学难题
Diagnostics (Basel). 2025 Aug 4;15(15):1957. doi: 10.3390/diagnostics15151957.
3
Cellular origins of mucinous ovarian carcinoma.
黏液性卵巢癌的细胞起源
J Pathol. 2025 May;266(1):9-25. doi: 10.1002/path.6407. Epub 2025 Mar 3.
4
Clinicopathological Analysis of Ovarian Neoplasms at a Tertiary Care Teaching Institute of North Malabar: A Four-Year Retrospective Study.北马拉巴尔三级护理教学机构卵巢肿瘤的临床病理分析:一项四年回顾性研究。
Cureus. 2025 Jan 17;17(1):e77574. doi: 10.7759/cureus.77574. eCollection 2025 Jan.
5
Multimodal diagnostic strategies and precision medicine in mucinous ovarian carcinoma: a comprehensive approach.黏液性卵巢癌的多模态诊断策略与精准医学:一种综合方法
Front Oncol. 2024 Jul 8;14:1391910. doi: 10.3389/fonc.2024.1391910. eCollection 2024.
6
Mature cystic teratoma with co-existent mucinous cystadenocarcinoma: describing a diagnostic challenge-a case report.成熟囊性畸胎瘤伴共存黏液性囊腺癌:描述诊断挑战-病例报告。
J Med Case Rep. 2024 May 5;18(1):232. doi: 10.1186/s13256-024-04544-w.
7
Primary Retroperitoneal Carcinomas: New Insights into Pathogenesis and Clinical Management in Comparison with Ovarian Carcinomas and Carcinoma of Unknown Primary.原发性腹膜后癌:与卵巢癌及原发灶不明癌相比,发病机制及临床管理的新见解
Cancers (Basel). 2023 Sep 18;15(18):4614. doi: 10.3390/cancers15184614.
8
[Mucinous tumors of the peritoneum].[腹膜黏液性肿瘤]
Chirurgie (Heidelb). 2023 Oct;94(10):823-831. doi: 10.1007/s00104-023-01926-6. Epub 2023 Jul 7.
9
Mucinous tumors arising from ovarian teratomas as another source of pseudomyxoma peritoneii: MR findings comparison with ovarian metastases from appendiceal mucinous tumors.卵巢畸胎瘤来源的黏液性肿瘤作为腹膜假黏液瘤的另一来源:与阑尾黏液性肿瘤的卵巢转移瘤的磁共振成像表现比较
BJR Open. 2023 Apr 19;5(1):20220036. doi: 10.1259/bjro.20220036. eCollection 2023.
10
[Mature teratoma with malignant differentiation treated with peritonectomy with HIPEC].[采用腹膜切除术联合腹腔内热灌注化疗治疗的伴有恶性分化的成熟畸胎瘤]
Rev Med Inst Mex Seguro Soc. 2023 Jan 2;61(1):111-116.